ArticleMolecular therapy : the journal of the American Society of Gene Therapy2014
Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
137 citing papers in PubMed, 2 syntheses or guidelines pooled it, 197 citations in OpenAlex.
- A Decade in Review: A Systematic Review of Universal Influenza Vaccines in Clinical Trials during the 2010 Decade.Viruses · 2020Pooled it
- Viral vector-based influenza vaccines.Human vaccines & immunotherapeutics · 2016Pooled it
- Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.Journal for immunotherapy of cancer · 2020Trial
- Trial
- Trial
- DNA-based vaccines: Advances, applications, and future prospects.Genes & diseases · 2026Review
- Advances in the Development of a Universal Influenza Vaccine.Antibodies (Basel, Switzerland) · 2026Review
- Critical Path to First-in-Human Batches of ChAdOx Vectors, Including for Emergency Response.Vaccines · 2026Article
- T-cell-mediated immunity to influenza A (H2N3): implications for caccine efficacy and cross-subtype protection.Archives of microbiology · 2026Review
- Developing the next-generation of adenoviral vector vaccines.Human vaccines & immunotherapeutics · 2025Review
- Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2.Vaccines · 2025Review
- Application of Humanized MHC Transgenic Mice in the Screening of HLA-Restricted T Cell Epitopes for Influenza Vaccines.Vaccines · 2025Article
- Heterologous prime-boost Zika virus vaccination induces comprehensive humoral and cellular immunity in mouse models.Frontiers in immunology · 2025Article
- Review
- Current perspectives on vaccines and therapeutics for Lassa Fever.Virology journal · 2024Review
- Immunogenic recombinant Mayaro virus-like particles present natively assembled glycoprotein.NPJ vaccines · 2024Article
- Viral-vectored boosting of OmcB- or CPAF-specific T-cell responses fail to enhance protection from Chlamydia muridarum in infection-immune mice and elicits a non-protective CD8-dominant response in naïve mice.Mucosal immunology · 2024Article
- Immunity and Protective Efficacy of a Plant-Based Tobacco Mosaic Virus-like Nanoparticle Vaccine against Influenza a Virus in Mice.Vaccines · 2024Article
- Systemic prime mucosal boost significantly increases protective efficacy of bivalent RSV influenza viral vectored vaccine.NPJ vaccines · 2024Article
- Role of homologous recombination/recombineering on human adenovirus genome engineering: Not the only but the most competent solution.Engineering microbiology · 2024Review
77 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Adenoviruses are potent vectors for inducing and boosting cellular immunity to encoded recombinant antigens. However, the widespread seroprevalence of neutralizing antibodies to common human adenovirus serotypes limits their use. Simian adenoviruses do not suffer from the same drawbacks. We have constructed a replication-deficient chimpanzee adenovirus-vectored vaccine expressing the conserved influenza antigens, nucleoprotein (NP), and matrix protein 1 (M1). Here, we report safety and T-cell immunogenicity following vaccination with this novel recombinant simian adenovirus, ChAdOx1 NP+M1, in a first in human dose-escalation study using a 3+3 study design, followed by boosting with modified vaccinia virus Ankara expressing the same antigens in some volunteers. We demonstrate ChAdOx1 NP+M1 to be safe and immunogenic. ChAdOx1 is a promising vaccine vector that could be used to deliver vaccine antigens where strong cellular immune responses are required for protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.